1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Brian Hill: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Ixazomib, Lenalidomide, Rituximab - B Cell Lymphoma, Lymphoma | Phase 1 / Phase 2 | Terminated | Brian Hill | 19 | 2017-02-20 | 2022-09-26 |
Lymphoma (1) · Lymphoma, B-Cell (1)
Lenalidomide (1) · Rituximab (1) · ixazomib (1)
United States (1)